Timothy J Henrich

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. doi request reprint HIV-1 entry inhibitors: recent development and clinical use
    Timothy J Henrich
    Division of Infectious Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Curr Opin Virol 3:51-7. 2013
  2. pmc Increased risk of virologic rebound in patients on antiviral therapy with a detectable HIV load <48 copies/mL
    Timothy J Henrich
    Division of Infectious Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 7:e50065. 2012
  3. doi request reprint Impact of age, gender, and pregnancy on syphilis screening using the Captia Syphilis-G assay
    Timothy J Henrich
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Sex Transm Dis 38:1126-30. 2011
  4. pmc Low-level detection and quantitation of cellular HIV-1 DNA and 2-LTR circles using droplet digital PCR
    Timothy J Henrich
    Division of Infectious Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02119, USA
    J Virol Methods 186:68-72. 2012
  5. ncbi request reprint Association of alcohol abuse and injection drug use with immunologic and virologic responses to HAART in HIV-positive patients from urban community health clinics
    Timothy J Henrich
    Department of Internal Medicine, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    J Community Health 33:69-77. 2008
  6. pmc Clinical risk factors for severe Clostridium difficile-associated disease
    Timothy J Henrich
    Division of Infectious Diseases, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Emerg Infect Dis 15:415-22. 2009
  7. doi request reprint Disseminated Geotrichum candidum infection in a patient with relapsed acute myelogenous leukemia following allogeneic stem cell transplantation and review of the literature
    T J Henrich
    Division of Infectious Diseases, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Transpl Infect Dis 11:458-62. 2009
  8. pmc Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists
    Timothy J Henrich
    Brigham and Women s Hospital, Boston, Massachusetts, USA
    Antimicrob Agents Chemother 56:1931-5. 2012
  9. pmc Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate
    Timothy J Henrich
    Division of Infectious Diseases, Brigham and Women s Hospital, Boston, MA, USA
    J Acquir Immune Defic Syndr 55:420-7. 2010
  10. pmc Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation
    Timothy J Henrich
    Divison of Infectious Diseases, Brigham and Women s Hospital, Boston, Massachusetts, USA
    J Infect Dis 207:1694-702. 2013

Detail Information

Publications16

  1. doi request reprint HIV-1 entry inhibitors: recent development and clinical use
    Timothy J Henrich
    Division of Infectious Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Curr Opin Virol 3:51-7. 2013
    ..This review provides an overview of HIV-1 entry inhibitors, with a focus on drugs in the later stages of clinical development...
  2. pmc Increased risk of virologic rebound in patients on antiviral therapy with a detectable HIV load <48 copies/mL
    Timothy J Henrich
    Division of Infectious Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 7:e50065. 2012
    ..A detectable VL <48 copies/mL was independently and significantly associated with subsequent viral rebound, and is cause for clinical concern...
  3. doi request reprint Impact of age, gender, and pregnancy on syphilis screening using the Captia Syphilis-G assay
    Timothy J Henrich
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Sex Transm Dis 38:1126-30. 2011
    ....
  4. pmc Low-level detection and quantitation of cellular HIV-1 DNA and 2-LTR circles using droplet digital PCR
    Timothy J Henrich
    Division of Infectious Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02119, USA
    J Virol Methods 186:68-72. 2012
    ..ddPCR is a promising novel technology for the study of HIV-1 reservoirs and persistence, but further optimization of this novel technology would enhance the detection of very low-level viral genetic targets...
  5. ncbi request reprint Association of alcohol abuse and injection drug use with immunologic and virologic responses to HAART in HIV-positive patients from urban community health clinics
    Timothy J Henrich
    Department of Internal Medicine, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    J Community Health 33:69-77. 2008
    ..This study highlights the importance for clinicians of understanding the negative associations of substance abuse with the treatment response of HIV-infected patients at urban health centers...
  6. pmc Clinical risk factors for severe Clostridium difficile-associated disease
    Timothy J Henrich
    Division of Infectious Diseases, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Emerg Infect Dis 15:415-22. 2009
    ..06), and computed tomography scan showing colorectal inflammation (OR 13.54). These clinical and laboratory markers for severe disease may be useful for identifying patients at risk for serious outcomes or death...
  7. doi request reprint Disseminated Geotrichum candidum infection in a patient with relapsed acute myelogenous leukemia following allogeneic stem cell transplantation and review of the literature
    T J Henrich
    Division of Infectious Diseases, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Transpl Infect Dis 11:458-62. 2009
    ..We review the literature regarding invasive infections with G. candidum, which predominantly affect immunocompromised hosts, and discuss potential therapies for this rare pathogen...
  8. pmc Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists
    Timothy J Henrich
    Brigham and Women s Hospital, Boston, Massachusetts, USA
    Antimicrob Agents Chemother 56:1931-5. 2012
    ..This heterogeneity makes it difficult to draw general conclusions about the relationship between patterns of CCR5 antagonist resistance and the use of specific CCR5 domains for entry...
  9. pmc Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate
    Timothy J Henrich
    Division of Infectious Diseases, Brigham and Women s Hospital, Boston, MA, USA
    J Acquir Immune Defic Syndr 55:420-7. 2010
    ..Here, we test the contribution of gp120 mutations to CCR5 antagonist resistance and investigate why certain minority V3 variants emerged as the dominant species under drug pressure...
  10. pmc Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation
    Timothy J Henrich
    Divison of Infectious Diseases, Brigham and Women s Hospital, Boston, Massachusetts, USA
    J Infect Dis 207:1694-702. 2013
    ..The long-term impact of allogeneic hematopoietic stem cell transplantation (HSCT) on human immunodeficiency virus type 1 (HIV-1) reservoirs in patients receiving combination antiretroviral therapy (cART) is largely unknown...
  11. pmc HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug
    Opass Putcharoen
    Brigham and Women s Hospital, Boston, Massachusetts, USA
    J Virol 86:1119-28. 2012
    ..We propose that the restoration of pre-CCR5 antagonist therapy HIV entry kinetics drives the selection of V3 loop mutations and may represent a common mechanism that underlies the emergence of CCR5 antagonist resistance...
  12. pmc Xenotropic murine leukemia virus-related virus prevalence in patients with chronic fatigue syndrome or chronic immunomodulatory conditions
    Timothy J Henrich
    Division of Infectious Diseases, Brigham and Women s Hospital, Boston, Massachusetts, USA
    J Infect Dis 202:1478-81. 2010
    ..XMRV DNA was not detected in any participant samples. We found no association between XMRV and patients with chronic fatigue syndrome or chronic immunomodulatory conditions...
  13. pmc Instantaneous inhibitory potential is similar to inhibitory quotient at predicting HIV-1 response to antiretroviral therapy
    Timothy J Henrich
    Division of Infectious Disease, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Clin Infect Dis 51:93-8. 2010
    ..However, there are no quantitative analyses supporting this hypothesis...
  14. pmc SHIV-162P3 infection of rhesus macaques given maraviroc gel vaginally does not involve resistant viruses
    Athe M N Tsibris
    Massachusetts General Hospital, Boston, Massachusetts, United States of America
    PLoS ONE 6:e28047. 2011
    ..These data suggest that breakthrough infections most likely result from incomplete viral inhibition and not the selection of MVC-resistant variants...
  15. doi request reprint HIV-2 encephalitis: case report and literature review
    Brian R Wood
    Division of Infectious Disease, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    AIDS Patient Care STDS 26:383-7. 2012
    ....
  16. pmc Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211
    Athe M N Tsibris
    Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Clin Infect Dis 48:642-9. 2009
    ....